Ivan Balabanov

But when you're looking at bigger scope, percentage wise, the idea is to just just as you said, in your own words in, in just over arousal, correct. That's a very big distinction between the two. Yeah, I'll correct myself. Yeah, yeah. Yeah. But But so reducing over arousal, it's not the same as restoring joy. It's I'm not saying it's a bad thing. It's not. Okay. Okay. Now,

But when you're looking at bigger scope, percentage wise, the idea is to just just as you said, in your own words in, in just over arousal, correct. That's a very big distinction between the two. Yeah, I'll correct myself. Yeah, yeah. Yeah. But But so reducing over arousal, it's not the same as restoring joy. It's I'm not saying it's a bad thing. It's not. Okay. Okay. Now,

The opposite of depression or anxiety or all of this, it's not happiness. It's really not. I will tell, like, I don't know where I heard it. I think it was one of these current kind of big names. But anyway, when she said this, it really hit home base for me. The opposite is actually curiosity. You want curiosity, you want some, I'm intrigued, I can recognize novelty.

The opposite of depression or anxiety or all of this, it's not happiness. It's really not. I will tell, like, I don't know where I heard it. I think it was one of these current kind of big names. But anyway, when she said this, it really hit home base for me. The opposite is actually curiosity. You want curiosity, you want some, I'm intrigued, I can recognize novelty.

As a dog trainer, when I have a behavior problem, if I have a dog that doesn't have curiosity, I will struggle. I will really, really struggle, right?

As a dog trainer, when I have a behavior problem, if I have a dog that doesn't have curiosity, I will struggle. I will really, really struggle, right?

actually, like it is very hard to evaluate something that you don't even know what you're diagnosing to begin with. Like I will tell you, and again, this all comes from human psychiatry and the problems that they are facing and that are actually really challenging right now. One of the interesting things is that

actually, like it is very hard to evaluate something that you don't even know what you're diagnosing to begin with. Like I will tell you, and again, this all comes from human psychiatry and the problems that they are facing and that are actually really challenging right now. One of the interesting things is that

all of the studies that come out that actually big pharma allow to come out because there is studies that, like you cannot see a study that's bad. You have to do a serious homework for that.

all of the studies that come out that actually big pharma allow to come out because there is studies that, like you cannot see a study that's bad. You have to do a serious homework for that.

Right. But the companies like Lilly's and whatever, they want to make money. They want to make money. They have no interest to publish those studies. We know everybody agrees on that. One of the interesting things where I was going with this is that most of the, even the studies that do come out, they're done within, again, this eight weeks of time.

Right. But the companies like Lilly's and whatever, they want to make money. They want to make money. They have no interest to publish those studies. We know everybody agrees on that. One of the interesting things where I was going with this is that most of the, even the studies that do come out, they're done within, again, this eight weeks of time.

And as you said, from there on, we are putting somebody for three years or perhaps for life on that medication.

And as you said, from there on, we are putting somebody for three years or perhaps for life on that medication.

How is that eight weeks a baseline of what's going to happen?

How is that eight weeks a baseline of what's going to happen?

I mean, it's very impossible to, to evaluate how the drug affects your brain within eight weeks, and what happens in long term. These are two tweezers, apples and oranges.

I mean, it's very impossible to, to evaluate how the drug affects your brain within eight weeks, and what happens in long term. These are two tweezers, apples and oranges.

We'll get there. Let's not.

We'll get there. Let's not.